HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Jiangsu Recbio Technology / Equity Capital Markets

<p>In recent years, driven by global public health event such as COVID-19, vaccine R&amp;D and production have gradually attracted wide attention in the market. More and more vaccine companies have begun to develop innovative vaccines with the support of capital, and <a href="https://www.smartkarma.com/entities/jiangsu-recbio-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33810:1" rel="noopener">Jiangsu Recbio Technology (JRT HK)</a> is one of them. On July 16, 2021, Recbio submitted its prospectus to the HKEX for the application of listing on the main board. This insight mainly analyzed the industry characteristics, the pipeline and related concerns of the Company.</p>

In recent years, driven by global public health event such as COVID-19, vaccine R&amp;D and production have gradually attracted wide attention in the market. More and more vaccine companies have begun to develop innovative vaccines with the support of capital, and Jiangsu Recbio Technology (JRT HK) is one of them. On July 16, 2021, Recbio submitted its prospectus to the HKEX for the application of listing on the main board. This insight mainly analyzed the industry characteristics, the pipeline and related concerns of the Company.

Pre-IPO Jiangsu Recbio Technology - There Are Many Uncertainties

Beijing Advaccine Biotechnology / Equity Capital Markets

<p>No one could have imagined that the world of 2020 would be radically changed by the COVID-19. The invisible virus is so fierce, and humans, surrounded by high technology, are so fragile that they have to rely on vaccines to return to normal life. With hundreds of COVID-19 vaccine R&amp;D teams around the world working hard to develop vaccines, it is not known who would be the terminator of COVID-19. <a href="https://www.smartkarma.com/entities/beijing-advaccine-biotechnology-co-ltd" target="_blank" data-smartkarma-citation="entities:33147:1" rel="noopener">Beijing Advaccine Biotechnology (BAB HK)</a> is one of them. On April 26, Advaccine, an innovative vaccine company, filed an application to list on the main board of the Hong Kong Stock Exchange, and the core product is a vaccine candidate for COVID-19. So could Advaccine become the terminator? This insights mainly analyzed the vaccine candidates in the pipeline.</p>

No one could have imagined that the world of 2020 would be radically changed by the COVID-19. The invisible virus is so fierce, and humans, surrounded by high technology, are so fragile that they have to rely on vaccines to return to normal life. With hundreds of COVID-19 vaccine R&amp;D teams around the world working hard to develop vaccines, it is not known who would be the terminator of COVID-19. Beijing Advaccine Biotechnology (BAB HK) is one of them. On April 26, Advaccine, an innovative vaccine company, filed an application to list on the main board of the Hong Kong Stock Exchange, and the core product is a vaccine candidate for COVID-19. So could Advaccine become the terminator? This insights mainly analyzed the vaccine candidates in the pipeline.

Pre-IPO Beijing Advaccine Biotechnology - Would the “new Force” Become the Terminator of COVID-19?

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Beijing Advaccine Biotechnology (BAB HK)

Pre-IPO Jiangsu Recbio Technology - There Are Many Uncertainties

This article mainly analyzed Recbio Technology in terms of the vaccine industry characteristics, core product candidates (HPV vaccines, COVID-19...

Xinyao (Criss) Wang

Pre-IPO Beijing Advaccine Biotechnology - Would the “new Force” Become the Terminator of COVID-19?

As a "new force" in the domestic innovative vaccine R&D, Advaccine's core vaccine candidates, the mechanism, and the technology platforms are...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)